News
HOOK
0.860
-0.58%
-0.005
Weekly Report: what happened at HOOK last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at HOOK last week (1117-1121)?
Weekly Report · 11/24 10:14
Weekly Report: what happened at HOOK last week (1110-1114)?
Weekly Report · 11/17 10:14
Weekly Report: what happened at HOOK last week (1103-1107)?
Weekly Report · 11/10 10:12
Weekly Report: what happened at HOOK last week (1027-1031)?
Weekly Report · 11/03 10:12
Hookipa Pharma completes sale of HBV, HIV assets to Gilead
TipRanks · 10/31 12:11
Weekly Report: what happened at HOOK last week (1020-1024)?
Weekly Report · 10/27 10:15
Weekly Report: what happened at HOOK last week (1013-1017)?
Weekly Report · 10/20 10:12
Weekly Report: what happened at HOOK last week (1006-1010)?
Weekly Report · 10/13 10:14
Hookipa Pharma CEO Makes a Strategic Stock Move
TipRanks · 10/10 02:02
Weekly Report: what happened at HOOK last week (0929-1003)?
Weekly Report · 10/06 10:11
Weekly Report: what happened at HOOK last week (0922-0926)?
Weekly Report · 09/29 10:12
Weekly Report: what happened at HOOK last week (0915-0919)?
Weekly Report · 09/22 10:12
Tracking Baker Brothers Portfolio - Q2 2025 Update
Seeking Alpha · 09/16 00:21
Weekly Report: what happened at HOOK last week (0908-0912)?
Weekly Report · 09/15 09:21
Weekly Report: what happened at HOOK last week (0901-0905)?
Weekly Report · 09/08 09:23
Weekly Report: what happened at HOOK last week (0825-0829)?
Weekly Report · 09/01 09:21
Weekly Report: what happened at HOOK last week (0818-0822)?
Weekly Report · 08/25 09:23
Weekly Report: what happened at HOOK last week (0811-0815)?
Weekly Report · 08/18 09:22
Weekly Report: what happened at HOOK last week (0804-0808)?
Weekly Report · 08/11 09:22
More
Webull provides a variety of real-time HOOK stock news. You can receive the latest news about Hookipa Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HOOK
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its proprietary arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers.